Health Care·Biotechnology·$5.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.27 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.27 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their commitment to pipeline development. However, they did not offer any updates on future earnings expectations.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline.
Xenon Pharmaceutical's earnings report showed a loss per share of $0.27, but the stock rose by 1.62% following the announcement. The increase in stock price may reflect investor optimism about the company's ongoing projects, despite the lack of revenue data and guidance. The absence of specific future guidance leaves some uncertainty for investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RBC BEARINGS INC
Nov 9, 2015